EX-10.110-Q·CIK 1826892·0001193125-26-462306

First Amendment to License Agreement

View original filing on SEC EDGAR → ·  seen Nov 16, 2026, 09:01 EST

Exhibit 10.1

FIRST AMENDMENT TO LICENSE AGREEMENT

This FIRST AMENDMENT (the “First Amendment”) is made and entered into as of August 12, 2026 (“Amendment Effective Date”), by and between EXUMA Biotech Corp. (formerly F1 Oncology, Inc.), a Delaware corporation (“EXUMA”), and BioAtla, Inc., a Delaware corporation (as successor to BioAtla LLC) (“BioAtla”). Each of Exuma and BioAtla is sometimes referred to individually in this First Amendment as a “Party” and collectively as the “Parties.”

WHEREAS,BioAtla and EXUMA are parties to that certain Amended and Restated Exclusive License Agreement, dated November 22, 2019 (the “Agreement”);

WHEREAS, subject to the terms and conditions of the Agreement as amended by this First Amendment, (a) EXUMA proposes to pay to BioAtla, and BioAtla desires to accept, the Amendment Pay-Off Amount described below to satisfy in full any and all royalty payments contemplated by Section 3 of the Agreement and (b) BioAtla proposes to grant, and EXUMA proposes to accept such grant, of a royalty-free, fully paid-up, non-terminable right and license under the BioAtla Licensed Technology pursuant to the Exclusive ACT License (each as defined below); and

WHEREAS, BioAtla and EXUMA now wish to amend the Agreement as set forth herein.

NOW, THEREFORE, in consideration of the premises, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:

1.

Defined Terms. Capitalized terms used and not defined in this First Amendment shall have the meanings ascribed to them in the Agreement.

2.

Amendment Pay-Off Amount. In full consideration for the License and other rights granted by BioAtla under the Agreement, including this First Amendment, EXUMA shall pay to BioAtla US$250,000.00 in immediately available funds within two (2) Business Days following the Amendment Effective Date as a non-refundable, non-creditable payment (the “Amendment Pay-Off Amount”)

3.

Royalty-Free, Fully Paid-Up, Non-Terminable License; Patent Costs. Effective upon receipt by BioAtla of the Amendment Pay-Off Amount as contemplated by Section 2: (a) BioAtla hereby confirms and agrees that the Exclusive ACT License shall be and become royalty-free, fully paid-up, irrevocable, perpetual and non-terminable right and license under the BioAtla Licensed Technology pursuant to the Exclusive ACT License, and (b) EXUMA shall be responsible for all Joint Patent costs contemplated by Section 5.2(c), whether currently outstanding and existing or otherwise due and owing in the future at any time. For clarity, the foregoing applies to the Exclusive ACT License in its entirety, including BioAtla's and its Affiliates’ interest in the Joint Technology, and the Exclusive ACT License shall remain exclusive, royalty-free, fully paid-up, irrevocable and perpetual notwithstanding Sections 7.1 and 7.3 of the Agreement. Sections 3.2 through 3.9 of the Agreement shall terminate upon such receipt.

4.

Miscellaneous. Except as provided in Sections 1, 2 and 3, all other terms of the Agreement shall remain in full force and effect. The Agreement, as amended by this First Amendment, constitutes the entire agreement between the parties with respect to the subject matter thereof. This First Amendment may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party; provided that a facsimile signature shall be considered due execution and shall be binding upon the signatory thereto with the same force and effect as if the signature were an original, not a facsimile signature.

[Signature Page Follows]


IN WITNESS WHEREOF, the Parties have signed this First Amendment as of the Amendment Effective Date.

EXUMA BIOTECH CORP.

By: /s/ Gregory I. Frost

Name: Gregory I. Frost

Title: Chief Executive Officer

BIOATLA, INC.

By: /s/ Jay Short

Name: Jay Short

Title: Chief Executive Officer


Back to all agreements